```
<!--StartFragment-->RESULT 4
ABB78741
ID   ABB78741 standard; protein; 89 AA.
XX
AC   ABB78741;
XX
DT   22-JUL-2002  (first entry)
XX
DE   Human calsyntenin-1 cleaved protein sequence SEQ ID NO:30.
XX
KW   Human; calsyntenin-1; calsyntenin-2; calsyntenin-3; nervous system;
KW   calcium binding protein; neuroprotective; antiinflammatory; nootropic;
KW   anticonvulsant; cerebroprotective; cytostatic; ophthalmological; tumour;
KW   analgesic; neuroleptic; vaccine; gene therapy; nervous system disorder;
KW   metastasis; ARP2/3 complex; neoangiogenesis; neurodegenerative disease;
KW   neuroinflammatory disease; epileptic seizure; retinal disease;
KW   pathological pain syndrome; psychiatric disorder.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO200222819-A2.
XX
PD   21-MAR-2002.
XX
PF   13-SEP-2001; 2001WO-IB001662.
XX
PR   14-SEP-2000; 2000EP-00810830.
XX
PA   (UYZU-) UNIV ZUERICH.
XX
PI   Sonderegger P,  Hintsch G,  Kinter J,  Meskenaite V,  Schrimpf S;
PI   Vogt L,  Zurlinden A;
XX
DR   WPI; 2002-404811/43.
XX
PT   Isolated nervous system calcium binding protein, selected from
PT   calsyntenin-1-3, useful as valuable agents for the treatment of disorders
PT   of nervous system and in the development of drugs.
XX
PS   Example 14; Page 76; 158pp; English.
XX
CC   The present invention describes an isolated nervous system calcium
CC   binding protein (I), selected from calsyntenin-1, calsyntenin-2 or
CC   calsyntenin-3, used as a pharmaceutical, having calcium binding activity
CC   and/or capable of binding Arp2/3 complex. (I) has neuroprotective,
CC   antiinflammatory, nootropic, anticonvulsant, cerebroprotective,
CC   cytostatic, ophthalmological, analgesic and neuroleptic activities. (I)
CC   and the polynucleotide encoding it (II) can be used in vaccines and in
CC   gene therapy. (I) and (II) are useful for the screening and for the
CC   preparation of a medicament for the treatment of disorders, in particular
CC   disorders of nervous system, particularly central nervous system
CC   including brain. (I) and (II) are also useful for the preparation of a
CC   medicament for the treatment of tumours including prevention or reduction
CC   of growth, expansion infiltration and metastasis of primary and
CC   metastatic tumours, in particular brain tumour or tumours of retina,
CC   where the tumours involve an enhanced activity of ARP2/3 complex or
CC   protease functionally connected with (I), in their growth, expansion,
CC   infiltration, metastasis and promotion of blood vessels or
CC   neoangiogenesis. (I) and (II) are also useful for treating, preventing or
CC   ameliorating the negative effects of neurodegenerative diseases or
CC   neuroinflammatory diseases or epileptic seizures, and for treating,
CC   ameliorating or preventing retinal diseases, pathological pain syndromes,
CC   psychiatric disorders, learning and memory functions in healthy persons,
CC   and for treating tumours. The present sequence represents a human
CC   calsyntenin-1 cleaved protein sequence, which is used in an example from
CC   the present invention
XX
SQ   Sequence 89 AA;

  Query Match          100.0%;  Score 104;  DB 5;  Length 89;
  Best Local Similarity  100.0%;  Pred. No. 9.4e-09;
  Matches   19;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 QFVHPEHRSFVDLSGHNLA 19
              |||||||||||||||||||
```

```
Db          57 QFVHPEHRSFVDLSGHNLA 75

<!--EndFragment-->
```